Skip to main content

US ClosedU.S. Closed

HURA: TuHURA Biosciences, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development.

52W Range

56thpctl

Volume

0.19×avg

Market Cap

134.37MUSD

P/E Ratio

-3.9TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

TuHURA Biosciences, Inc.

HURANASDAQ Capital Market·USD·Closed

TuHURA Biosciences, Inc.

HURANASDAQ·USD·Closed

$2.11

−0.94%

$2.11

−$0.02 (0.94%)

52W Range

56thpctl

Volume

0.19×avg

Mkt Cap

134.37MUSD

P/E

-3.9TTM

Div Yield

–ann